Intellia Therapeutics, Inc. (NASDAQ:NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT
Company Participants
Jason Fredette
John Leonard – President, CEO & Director
David Lebwohl – Executive VP & Chief Medical Officer
Conference Call Participants
Maurice Raycroft – Jefferies LLC, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Lili Nsongo – Leerink Partners LLC, Research Division
Joseph Thome – TD Cowen, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Terence Flynn – Morgan Stanley, Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
William Pickering – Sanford C. Bernstein & Co., LLC., Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
Yanan Zhu – Wells Fargo Securities, LLC, Research Division
Joon Lee – Truist Securities, Inc., Research Division
Mitchell Kapoor – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good morning, everyone, and welcome to Intellia Therapeutics conference call. My name is Jamie, and I will be the conference operator today. Please be advised that this call is being recorded at the company’s request. [Operator Instructions]
At this time, I’d like to turn the conference call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Jason Fredette
Thank you, operator and hello, everyone. This morning, we issued a press release and filed an 8-K regarding a safety event that occurred in our MAGNITUDE Phase III clinical trial of next-z. Those documents can be accessed on our website, intelliatx.com, and the 8-K also can be accessed at sec.gov.
Before we get started, please note that during this call, Intellia management may make forward-looking statements. We ask that you refer to our SEC filings, which are available at sec.gov for a discussion of potential risks and uncertainties that
